Table 6. Muscle structure effects, cost-effectiveness assessment, and recommended procedure techniques.
| Muscle structure effects | |||||
|---|---|---|---|---|---|
| SRN | Year (country) | Type | Sample (age)* | RP | Adverse events |
| 90 | 2021 (South Korea) | CT | 15 (2–12) | NI | NI |
| 91 | 2019 (South Korea) | CT | 14 (2–10) | P | discomfort, decline in general condition, headache, dry mouth, pain at the injection site, viral infection, dizziness, back pain, and fatigue |
| 92 | 2019 (Belgium) | CT | 67 (7–11) | P | NI |
| 93 | 2018 (Australia) | PC | 11 (5–13) | NI | A |
| 94 | 2017 (Turkey) | PC | 12 (6–14) | NI | A |
| 95 | 2014 (Brazil) | SR | 480 (1.5–16) | POT | NI |
| 96 | 2014 (South Korea) | PC | 13 (4–8) | P | A |
| 97 | 2022 (Belgium) | PC | 26 (2–9) | P | A |
| Cost-effectiveness assessment | |||||
| 4 | 2020 (Netherlands) | CES | 60 (NI) | P | NI |
| Recommended procedural techniques | |||||
| 98 | 2018 (USA) | SC | 307 (NI) | NI | NI |
| 99 | 2018 (Turkey) | CT | 25 (3–16) | P | A |
| 100 | 2018 (USA) | CT | 14 (4–13) | NI | A |
| 101 | 2018 (USA) | RC | 249 (5–9) | NI | NI |
| 102 | 2017 (Thailand) | CS | 116 (30–46) | NI | NI |
| 103 | 2016 (Netherlands) | PC | 75 (4–18) | NI | NI |
| 104 | 2013 (Netherlands) | CT | NI | NI | NI |
| 105 | 2020 (France) | CT | 59 (5–11) | NI | NI |
*Years. SRN: study reference number; RP: rehabilitation program; CT: clinical trial; NI: not informed; P: physiotherapy; PC: prospective cohort; A: absent; SR: systematic review; POT: physiotherapy and occupational therapy; CES: cost-effectiveness study; SC: specialists’ consensus; RC: retrospective cohort; CS: case series.